169 related articles for article (PubMed ID: 36400898)
1. Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics.
Panda M; Kalita E; Singh S; Kumar K; Prajapati VK
Mol Divers; 2023 Dec; 27(6):2577-2603. PubMed ID: 36400898
[TBL] [Abstract][Full Text] [Related]
2. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
3. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
4. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
[TBL] [Abstract][Full Text] [Related]
5. Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization.
Yang J; Lin S; Chen Z; Yang F; Guo L; Wang L; Duan Y; Zhang X; Dai Y; Yin K; Yu C; Yuan X; Sun H; He B; Cao Y; Ye H; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
PLoS Pathog; 2023 Nov; 19(11):e1011804. PubMed ID: 38033141
[TBL] [Abstract][Full Text] [Related]
6. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern.
Wagner TR; Schnepf D; Beer J; Ruetalo N; Klingel K; Kaiser PD; Junker D; Sauter M; Traenkle B; Frecot DI; Becker M; Schneiderhan-Marra N; Ohnemus A; Schwemmle M; Schindler M; Rothbauer U
EMBO Rep; 2022 Feb; 23(2):e53865. PubMed ID: 34927793
[TBL] [Abstract][Full Text] [Related]
7. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
[TBL] [Abstract][Full Text] [Related]
9. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.
Misson Mindrebo L; Liu H; Ozorowski G; Tran Q; Woehl J; Khalek I; Smith JM; Barman S; Zhao F; Keating C; Limbo O; Verma M; Liu J; Stanfield RL; Zhu X; Turner HL; Sok D; Huang PS; Burton DR; Ward AB; Wilson IA; Jardine JG
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2216612120. PubMed ID: 37276407
[TBL] [Abstract][Full Text] [Related]
10. Superimmunity by pan-sarbecovirus nanobodies.
Xiang Y; Huang W; Liu H; Sang Z; Nambulli S; Tubiana J; Williams KL; Duprex WP; Schneidman-Duhovny D; Wilson IA; Taylor DJ; Shi Y
Cell Rep; 2022 Jun; 39(13):111004. PubMed ID: 35738279
[TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
[TBL] [Abstract][Full Text] [Related]
12. Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2.
Pymm P; Redmond SJ; Dolezal O; Mordant F; Lopez E; Cooney JP; Davidson KC; Haycroft ER; Tan CW; Seneviratna R; Grimley SL; Purcell DFJ; Kent SJ; Wheatley AK; Wang LF; Leis A; Glukhova A; Pellegrini M; Chung AW; Subbarao K; Uldrich AP; Tham WH; Godfrey DI; Gherardin NA
iScience; 2022 Nov; 25(11):105259. PubMed ID: 36213007
[TBL] [Abstract][Full Text] [Related]
13. Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants.
Li Q; Humphries F; Girardin RC; Wallace A; Ejemel M; Amcheslavsky A; McMahon CT; Schiller ZA; Ma Z; Cruz J; Dupuis AP; Payne AF; Maryam A; Yilmaz NK; McDonough KA; Pierce BG; Schiffer CA; Kruse AC; Klempner MS; Cavacini LA; Fitzgerald KA; Wang Y
Front Immunol; 2022; 13():995412. PubMed ID: 36172366
[TBL] [Abstract][Full Text] [Related]
14. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
Verkhivker G
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
[TBL] [Abstract][Full Text] [Related]
15. Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models.
Rossotti MA; van Faassen H; Tran AT; Sheff J; Sandhu JK; Duque D; Hewitt M; Wen X; Bavananthasivam J; Beitari S; Matte K; Laroche G; Giguère PM; Gervais C; Stuible M; Guimond J; Perret S; Hussack G; Langlois MA; Durocher Y; Tanha J
Commun Biol; 2022 Sep; 5(1):933. PubMed ID: 36085335
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein.
Jiang X; Qin Q; Zhu H; Qian J; Huang Q
Int J Biol Macromol; 2024 Jan; 256(Pt 1):128191. PubMed ID: 38000614
[TBL] [Abstract][Full Text] [Related]
17. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.
Verkhivker G
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328351
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of nanobodies neutralizing SARS-CoV-2 variants.
Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y
Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082
[TBL] [Abstract][Full Text] [Related]
19. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J; Lilly M; Starr TN; Dadonaite B; Lovendahl KN; Croft JT; Stoddard CI; Chohan V; Ding S; Ruiz F; Kopp MS; Finzi A; Bloom JD; Chu HY; Lee KK; Overbaugh J
Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2220948120. PubMed ID: 37253011
[TBL] [Abstract][Full Text] [Related]
20. Antibody-nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants.
Nguyen H; Li MS
Sci Rep; 2022 Jun; 12(1):9701. PubMed ID: 35690632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
